Page last updated: 2024-09-04

levofloxacin and Pseudomonas Infections

levofloxacin has been researched along with Pseudomonas Infections in 98 studies

Research

Studies (98)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (3.06)	18.2507
2000's	31 (31.63)	29.6817
2010's	48 (48.98)	24.3611
2020's	16 (16.33)	2.80

Authors

Authors	Studies
Frigola, J; García-Granda, S; Gómez-Gomar, A; Ortega, E; Torrens, A; Vañó, D	1
Drusano, GL; Fregeau, C; Kulawy, R; Liu, W; Louie, A	1
Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K	1
Bulik, CC; Crandon, JL; Kuti, JL; Nicolau, DP	1
Agrawal, N; Barthlow, H; Bezdenejnih-Snyder, N; Breen, J; Carr, GR; Ciaccio, P; Comita-Prevoir, J; Cornebise, M; Cottone, A; Cronin, M; Dougherty, TJ; Ehmann, DE; Eyermann, CJ; Geng, B; Goteti, K; Hopkins, S; McNulty, J; Newman, JV; O'Donnell, J; Pandarinathan, L; Reck, F; Stone, G; Tang, X; Zhao, L	1
Chen, CL; Clark, RB; Deng, Y; Fyfe, C; Grossman, TH; He, M; Hunt, DK; Sun, C; Sutcliffe, JA; Xiao, XY	1
Akhtar, S; Ansari, MM; Ghosh, JK; Mitra, K; Pant, G; Pratap Verma, D; Saroj, J; Singh, BN; Verma, NK	1
Li, S; Matsuki, Y; Oda, T; Tanabe, S; Yokozawa, T	1
Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF	1
Chu, Y; Li, J; Liu, W; Prithiviraj, B; Wang, X; Wu, Y; Yang, X; Zeng, Q; Zhao, K; Zhou, H; Zhou, X	1
Campo-Beleño, C; Coria-Jimenez, R; Fernández-Presas, AM; Franco, B; Franco-Cendejas, R; García-Contreras, R; González, EE; Hernández-Durán, M; Jiménez-García, LF; Lara-Martínez, R; López-Jácome, LE; Morales-Espinosa, R; Muñoz-Carranza, S; Villamizar-Gallardo, RA	1
Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN	1
Ai, MY; Chen, BL; Chuang, HC; Lee, WY; Lee, YJ; Liu, HY; Lu, HE; Tsao, LH; Wang, EY	1
Ai, MY; Chen, BL; Chuang, HC; Huang, HW; Lee, YJ; Liu, HY; Tsao, LH; Wang, EY	1
Chaudhary, E; Kanta, S; Kumari, S; Rahi, DK; Razdan, K; Sinha, VR; Yadav, AK	1
Khan, M; Ma, K; Wan, I; Willcox, MD	1
Malnarcic, CM; McCaughan, J; Millar, BC; Moore, JE	1
He, X; Jian, L; Li, X; Zhao, L	1
Pliska, NN	1
Kubota, S; Kunii, M; Nakamura, H; Okamoto, M; Takei, D; Tanaka, F	1
Ahmad, I; Ejaz, H; Muzammil, S; Qamar, MU; Qureshi, R; Rasool, MH; Shafique, M	1
Elborn, JS; Flume, PA; Procaccianti, C; Van Devanter, DR	1
Duan, J; Gao, Y; Geng, X; Kang, J; Li, X; Song, Y; Wang, S; Yin, D; Zhang, R; Zhang, Z	1
Da Dalt, L; Guarnieri, M; Lucca, F; Muffato, G; Rigoli, R; Ros, M	1
Fung, CP; Lin, YT; Wang, FD; Wu, PF; Yang, TC	1
Moussa, K; Schallhorn, JM; Shantha, J	1
Chen, L; Luo, Z; She, P; Wu, Y	1
Fujimura, S; Hayakawa, S; Hirano, T; Kawamura, M; Kikuchi, T; Sato, T; Watanabe, A	1
Aoun, V; Chain, JL; Del'Orto, JC; Derbali, RM; Frei, G; Hildgen, P; Moussa, G; Roullin, VG; Tehrani, SF	1
Agnello, M; Bensman, J; Lou, M; Shriner, K; Sullivan, E; Wong-Beringer, A	1
Allan, B; Hau, S; Robbie, SJ; Tint, NL; Vega, FA	1
Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C	1
Chen, Y; Kong, J; Liu, W; Wu, H; Yan, P	1
Lee, WH; Li, SA; Liu, J; Wang, YJ; Xiang, Y; Zhang, Y	1
Coviello, T; D'Arrigo, G; Di Meo, C; Matricardi, P; Montanari, E; Passariello, C; Virga, A	1
Alba, L; Behta, M; Clock, SA; Della-Latta, P; Furuya, EY; Jenkins, SG; Jia, H; Kubin, CJ; Oliveira, AP; Patel, SJ; Rhee, K; Saiman, L; Schuetz, AN; Weisenberg, SA; Whittier, S; Zhou, JJ	1
Fujita, K; Goto, H; Hattori, T; Ito, N; Koike, N; Kumakura, S; Kuroda, M; Matsumoto, T; Miyake, T; Tajima, K; Yamaguchi, T	1
Fiel, SB	1
Galani, I; Giamarellos-Bourboulis, EJ; Pistiki, A; Safarika, A	1
Baluya, D; Brown, D; Drusano, GL; Fikes, S; Jelliffe, R; Kurhanewicz, S; Liu, W; Louie, A; Neely, MN; Robbins, N; Schumitzky, A; VanGuilder, M	1
Alm, RA; Corbeil, J; Déraspe, M; Gardner, H; Kos, VN; McLaughlin, RE; Roy, PH; Whiteaker, JD	1
Ampofo, K; Hillyard, B; Sherwin, CM; Spigarelli, MG; Stockmann, C	1
Eksi, F; Nazli, E; Zer, Y	1
Aaron, SD; Bell, SC; Conrad, D; Dudley, MN; Fischer, R; Flume, PA; Geller, DE; Kerem, E; Loutit, JS; Morgan, EE; Smyth, AR; Stuart Elborn, J; VanDevanter, DR	1
Cary, MS; Cluzet, VC; Fishman, NO; Lautenbach, E; Linkin, DR; Morales, KH; Nachamkin, I; Shih, NN	1
Cardoso, O; Gaspar, MC; Murtinho, D; Olivier, JC; Pais, AA; Serra, ME; Sousa, JJ; Tewes, F	1
Fujita, K; Goto, H; Hattori, T; Ito, N; Koike, N; Kuroda, M; Matsumoto, T; Miyake, T; Tajima, K; Takahashi, H	1
Castellanos-González, M; García-Martínez, FJ; López-Martín, I; Segurado-Rodríguez, MA	1
Cojutti, P; Cotta, MO; Della Rocca, G; Lugano, M; Pea, F; Roberts, JA	1
Candel, FJ; Cortés, JA; Guhl, G; Ibañez, A	1
Aaron, SD; Bell, SC; Conrad, D; Dudley, MN; Elborn, JS; Fischer, R; Flume, PA; Geller, DE; Kerem, E; Loutit, JS; Morgan, EE; Smyth, AR; VanDevanter, DR	1
Cohen, F; Elborn, JS; Flume, PA; Loutit, J; VanDevanter, DR	1
Bazzi, W; Hadi, U; Kissoyan, KA; Matar, GM	1
Alişkan, H; Güçlü, M; Husamettin, E; Serin, E; Yakar, T	1
Abuzeid, WM; Chiu, AG; Doghramji, L; Edelstein, PH; Guss, J	1
Citron, DM; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O	1
Chun, CL; Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Sun, KL	1
Bahniuk, N; Brown, DL; Drusano, GL; Grasso, C; Kulawy, R; Louie, A; Van Scoy, B	1
Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM	1
Deguchi, T; Matsumoto, T; Seike, K; Yasuda, M	1
Conrad, DJ; Fischer, R; Flume, PA; Geller, DE; Loutit, JS; Staab, D	1
Goto, H; Higaki, M; Honda, K; Ishii, H; Mikura, S; Nakamura, M; Okazaki, M; Tsunoda, T; Wada, H; Watanabe, T; Yasutake, T	1
Izard, D; Mullié, C; Sonnet, P	1
Hsu, LY; Kwa, AL; Lee, W; Lim, TP; Sasikala, S; Syahidah, N; Tan, TT; Tan, TY; Teo, J	1
Inoko, H; Ishii, Y; Kimura, S; Kouyama, Y; Mitsunaga, S; Mori, N; Tateda, K; Yamaguchi, K; Yoshihara, E	1
Baquero, F; Cantón, R; Fernández-Olmos, A; García-Castillo, M; Lamas, A; Maiz, L	1
Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT	1
Antoniu, SA; Azoicai, D	1
Erdem, I; Goktas, P; Kaya, B; Kaynar-Tascioglu, J	1
Marchetti, F; Trinchieri, A	1
Burgess, DS; Hall, RG; Hardin, TC	1
Forrest, A; Paladino, JA; Schentag, JJ; Sunderlin, JL	1
Marchetti, F; Viale, P	1
Dehghanyar, P; Georgopoulos, A; Heinz, G; Joukhadar, C; Mayer, BX; Müller, M; Neckel, U; Schenk, BS; Zeitlinger, MA	1
Colombo, A; De Vecchi, E; Drago, L; Gismondo, MR; Guerra, A; Medaglia, M; Nicola, L; Tocalli, L	1
Elliott, MA; Patel, R; Prabhu, RM	1
Corrado, M; Drusano, GL; Fowler, C; Kahn, J; Preston, SL; Weisinger, B	1
Schito, AM; Schito, GC	1
Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA	1
Di Bonaventura, G; Picciani, C; Piccolomini, R; Spedicato, I	1
Lister, PD; Wolter, DJ	1
Clarke, L; Elborn, JS; Goldsmith, CE; McCaughan, J; McKnight, AJ; Millar, BC; Moore, JE; Reid, A; Shaw, A	1
Hashimoto, H; Horii, T; Maekawa, M; Muramatsu, H; Takeshita, A	1
Felici, A; Guerrini, M; Marchetti, F; Piccoli, L	1
Marchese, A; Roveta, S; Schito, AM; Schito, GC	1
Burgmann, H; Hutschala, D; Jaksch, P; Mayer-Helm, BX; Müller, M; Skhirtladze, K; Tschernko, EM; Wisser, W; Wolner, E; Zuckermann, A	1
Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC	1
Carmeli, Y; Dodds, AE; Engemann, JJ; Kanafani, ZA; Kaye, KS; Weber, SG	1
Asbell, PA; Bottone, EJ; Epstein, SP	1
Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E	1
Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL	1
Amicosante, G; Celenza, G; Larosa, M; Perilli, M; Segatore, B; Setacci, D	1
Abad, JL; Alió, JL; Fernandez, J; Ferrer, C; Rodríguez, A	1
Amaratunga, DJ; Barrett, JF; Frosco, MB; Yagel, SK	1
Ishida, H; Ishida, Y; Kobayashi, H; Kurosaka, Y; Otani, T; Sato, K	1
Higashiyama, Y; Hirakata, Y; Kadota, J; Kaneko, Y; Kohno, S; Kuroki, M; Maesaki, S; Miyazaki, Y; Ohno, H; Sawai, T; Tashiro, T; Tomono, K; Yanagihara, K	1
Beach, ML; Jones, RN; Pfaller, MA	1
Gillespie, T; Masterton, RG	1

Reviews

9 review(s) available for levofloxacin and Pseudomonas Infections

Article	Year
Management of chronic Future microbiology, 2021, Volume: 16 Topics: Administration, Inhalation; Cystic Fibrosis; Humans; Levofloxacin; Persistent Infection; Pseudomonas Infections; Quality of Life	2021
Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Therapeutic advances in respiratory disease, 2014, Volume: 8, Issue:1 Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Clinical Trials as Topic; Cystic Fibrosis; Dose-Response Relationship, Drug; Dysgeusia; Humans; Levofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections	2014
Aerosolized antibiotics in cystic fibrosis: an update. Expert review of respiratory medicine, 2014, Volume: 8, Issue:3 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Aztreonam; Colistin; Cystic Fibrosis; Equipment Design; Humans; Levofloxacin; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin	2014
Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert review of respiratory medicine, 2015, Volume: 9, Issue:1 Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Chronic Disease; Cystic Fibrosis; Humans; Levofloxacin; Lung; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Time Factors; Treatment Outcome	2015
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatric pulmonology, 2013, Volume: 48, Issue:3 Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Drug Administration Schedule; Humans; Injections, Intravenous; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections	2013
MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:2 Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Clinical Trials as Topic; Drug Discovery; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Treatment Outcome	2013
Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:4 Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections	2003
Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 2 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity; Streptococcus pneumoniae	2004
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Current medical research and opinion, 2006, Volume: 22, Issue:5 Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Risk Factors; Treatment Outcome	2006

Trials

8 trial(s) available for levofloxacin and Pseudomonas Infections

Article	Year
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2015, Volume: 14, Issue:4 Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; Treatment Outcome; Young Adult	2015
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016, Volume: 15, Issue:4 Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Double-Blind Method; Drug Monitoring; Female; Forced Expiratory Volume; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Symptom Assessment; Symptom Flare Up; Treatment Outcome	2016
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2016, Volume: 15, Issue:5 Topics: Administration, Inhalation; Adult; Aerosols; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin; Treatment Outcome	2016
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. American journal of respiratory and critical care medicine, 2011, Jun-01, Volume: 183, Issue:11 Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Solutions; Sputum; Treatment Outcome	2011
[Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2003, Volume: 75, Issue:1 Topics: Anti-Infective Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Follow-Up Studies; Humans; Levofloxacin; Ofloxacin; Pseudomonas Infections; Recurrence; Safety; Staphylococcal Infections; Streptococcal Infections; Superinfection; Treatment Outcome; Urinary Tract; Urinary Tract Infections	2003
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy, 2003, Volume: 52, Issue:3 Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome	2003
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. The Journal of infectious diseases, 2004, May-01, Volume: 189, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Cross Infection; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcus aureus; Treatment Outcome	2004
Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest, 2007, Volume: 131, Issue:3 Topics: Adolescent; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Kidney Function Tests; Levofloxacin; Male; Metabolic Clearance Rate; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum	2007

Other Studies

81 other study(ies) available for levofloxacin and Pseudomonas Infections

Article	Year
7-Azetidinylquinolones as antibacterial agents. 3. Synthesis, properties and structure-activity relationships of the stereoisomers containing a 7-(3-amino-2-methyl-1-azetidinyl) moiety. Journal of medicinal chemistry, 1995, Mar-31, Volume: 38, Issue:7 Topics: Animals; Anti-Bacterial Agents; Azetidinecarboxylic Acid; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Escherichia coli Infections; Mice; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas Infections; Quinolones; Staphylococcal Infections; Stereoisomerism; Structure-Activity Relationship	1995
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Epithelium; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections	2009
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Female; Levofloxacin; Lung Diseases; Mice; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2009
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome	2010
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. Bioorganic & medicinal chemistry, 2014, Oct-01, Volume: 22, Issue:19 Topics: Animals; Chemistry, Physical; DNA Topoisomerases, Type II; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Humans; Mice; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Structure-Activity Relationship; Topoisomerase II Inhibitors	2014
Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents. Journal of medicinal chemistry, 2015, Jun-11, Volume: 58, Issue:11 Topics: Animals; Anti-Bacterial Agents; Bacteria; Drug Design; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship; Tetracyclines; Thigh	2015
Tandem Repeat of a Short Human Chemerin-Derived Peptide and Its Nontoxic d-Lysine-Containing Enantiomer Display Broad-Spectrum Antimicrobial and Antitubercular Activities. Journal of medicinal chemistry, 2021, 10-28, Volume: 64, Issue:20 Topics: Animals; Antimicrobial Peptides; Antitubercular Agents; Cell Survival; Chemokines; Dose-Response Relationship, Drug; Erythrocytes; Humans; Lysine; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Pseudomonas Infections; Stereoisomerism; Structure-Activity Relationship; THP-1 Cells	2021
Community-acquired Pseudomonas aeruginosa Osteomyelitis Caused by an Injury from a Dishwasher. Internal medicine (Tokyo, Japan), 2022, Aug-01, Volume: 61, Issue:15 Topics: Adult; Aged; Anti-Bacterial Agents; Female; Humans; Levofloxacin; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections	2022
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates. Translational vision science & technology, 2022, 05-02, Volume: 11, Issue:5 Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim	2022
Subinhibitory Cefotaxime and Levofloxacin Concentrations Contribute to Selection of Pseudomonas aeruginosa in Coculture with Staphylococcus aureus. Applied and environmental microbiology, 2022, 06-28, Volume: 88, Issue:12 Topics: Anti-Bacterial Agents; Bacterial Proteins; Cefotaxime; Coculture Techniques; Coinfection; Humans; Levofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Staphylococcal Infections; Staphylococcus aureus	2022
Biologically synthesized silver nanoparticles as potent antibacterial effective against multidrug-resistant Pseudomonas aeruginosa. Letters in applied microbiology, 2022, Volume: 75, Issue:3 Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Meropenem; Metal Nanoparticles; Microbial Sensitivity Tests; Plant Extracts; Pseudomonas aeruginosa; Pseudomonas Infections; Reactive Oxygen Species; Silver	2022
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran. International microbiology : the official journal of the Spanish Society for Microbiology, 2022, Volume: 25, Issue:4 Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors	2022
Development of a combination antibiogram for empirical treatments of Pseudomonas aeruginosa at a university-affiliated teaching hospital. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2023, Volume: 56, Issue:2 Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Ceftazidime; Fluoroquinolones; Gentamicins; Hospitals, Teaching; Humans; Levofloxacin; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Universities	2023
Correlation between antibiotic consumption and resistance of Pseudomonas aeruginosa in a teaching hospital implementing an antimicrobial stewardship program: A longitudinal observational study. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2023, Volume: 56, Issue:2 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Stewardship; Ciprofloxacin; Hospitals, Teaching; Humans; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections	2023
Levofloxacin loaded clove oil nanoscale emulgel promotes wound healing in Pseudomonas aeruginosa biofilm infected burn wound in mice. Colloids and surfaces. B, Biointerfaces, 2023, Volume: 222 Topics: Animals; Anti-Bacterial Agents; Biofilms; Burns; Clove Oil; Levofloxacin; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Wound Healing; Wound Infection	2023
Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates. Contact lens & anterior eye : the journal of the British Contact Lens Association, 2023, Volume: 46, Issue:3 Topics: Agar; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Gentamicins; Humans; Imipenem; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Piperacillin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2023
Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF). The clinical respiratory journal, 2020, Volume: 14, Issue:1 Topics: Anti-Bacterial Agents; Awareness; Ciprofloxacin; Cystic Fibrosis; Health Occupations; Humans; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections	2020
Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients. BMC pharmacology & toxicology, 2020, 03-04, Volume: 21, Issue:1 Topics: Anti-Bacterial Agents; Ceftazidime; Critical Illness; Drug Combinations; Drug Resistance, Bacterial; Humans; Kidney Diseases; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections	2020
Pseudomonas Aeruginosa as the Main Causative Agent of Osteomyelitis and its Susceptibility to Antibiotics. Drug research, 2020, Volume: 70, Issue:6 Topics: Amikacin; Anti-Bacterial Agents; Chronic Disease; Doripenem; Gentamicins; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies	2020
[A case of subacute hypertrophic pachymeningitis caused by Pseudomonas aeruginosa infection presenting with subdural hygroma]. Rinsho shinkeigaku = Clinical neurology, 2020, Aug-07, Volume: 60, Issue:8 Topics: Acute Disease; Administration, Oral; Aged; Female; Humans; Levofloxacin; Meningitis; Pseudomonas Infections; Subdural Effusion	2020
Antibacterial efficacy of silver nanoparticles against metallo-β-lactamase (blaNDM, blaVIM, blaOXA) producing clinically isolated Pseudomonas aeruginosa. Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:1(Suppleme Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Levofloxacin; Metal Nanoparticles; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections; Silver	2021
Deficiency of quorum sensing system inhibits the resistance selection of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin in vitro. Journal of global antimicrobial resistance, 2017, Volume: 10 Topics: Bacterial Proteins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Genes, Bacterial; Humans; Levofloxacin; Ligases; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Trans-Activators; Transcription Factors; Virulence Factors	2017
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013). The clinical respiratory journal, 2018, Volume: 12, Issue:7 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult	2018
Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia? Infection, 2018, Volume: 46, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Ciprofloxacin; Cohort Studies; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Taiwan; Treatment Outcome	2018
Blurry Vision and Eye Pain After Pterygium Surgery. JAMA ophthalmology, 2018, 07-01, Volume: 136, Issue:7 Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Eye Infections, Bacterial; Eye Pain; Female; Glucocorticoids; Humans; Indomethacin; Intraocular Pressure; Levofloxacin; Moxifloxacin; Ophthalmologic Surgical Procedures; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Pterygium; Scleritis; Vision Disorders; Visual Acuity	2018
Efficacy of levofloxacin against biofilms of Pseudomonas aeruginosa isolated from patients with respiratory tract infections in vitro. MicrobiologyOpen, 2019, Volume: 8, Issue:5 Topics: Anti-Bacterial Agents; Biofilms; China; Gene Expression Profiling; Humans; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Microscopy, Confocal; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sequence Analysis, RNA; Staining and Labeling	2019
An α-Lipoic acid derivative, and anti-ROS agent, prevents the acquisition of multi-drug resistance in clinical isolates of Pseudomonas aeruginosa. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:1 Topics: Anti-Bacterial Agents; Antioxidants; Bacterial Outer Membrane Proteins; Drug Resistance, Multiple, Bacterial; Histidine; Humans; Hydrogen Peroxide; Levofloxacin; Membrane Transport Proteins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Reactive Oxygen Species; Thioctic Acid	2019
Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study. Molecular pharmaceutics, 2019, 05-06, Volume: 16, Issue:5 Topics: A549 Cells; Anti-Bacterial Agents; Cell Survival; Cystic Fibrosis; Delayed-Action Preparations; Drug Compounding; Drug Evaluation, Preclinical; Drug Liberation; Drug Stability; Humans; Levofloxacin; Liposomes; Microbial Sensitivity Tests; Mucus; Nanoparticles; Pseudomonas aeruginosa; Pseudomonas Infections	2019
Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa. Critical care medicine, 2014, Volume: 42, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; Cross Infection; Drug Resistance, Microbial; Female; Fluoroquinolones; Hospital Mortality; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Virulence	2014
Perineural infiltrates in Pseudomonas keratitis. Journal of cataract and refractive surgery, 2013, Volume: 39, Issue:11 Topics: Adult; Anti-Bacterial Agents; Contact Lenses, Hydrophilic; Cornea; Corneal Ulcer; Cranial Nerve Diseases; Eye Infections, Bacterial; Female; Humans; Levofloxacin; Microscopy, Confocal; Ophthalmic Nerve; Pseudomonas aeruginosa; Pseudomonas Infections	2013
Prevention of catheter-related Pseudomonas aeruginosa infection by levofloxacin-impregnated catheters in vitro and in vivo. Chinese medical journal, 2014, Volume: 127, Issue:1 Topics: Animals; Biofilms; Catheters, Indwelling; Female; Levofloxacin; Mice; Pseudomonas aeruginosa; Pseudomonas Infections	2014
Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6 Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cationic Peptides; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Eye Infections, Bacterial; Gentamicins; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits	2014
Chasing bacteria within the cells using levofloxacin-loaded hyaluronic acid nanohydrogels. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, Volume: 87, Issue:3 Topics: Anti-Bacterial Agents; Cell Line, Tumor; Cholesterol; Drug Delivery Systems; Fluoroquinolones; HeLa Cells; Humans; Hyaluronic Acid; Hydrogels; Levofloxacin; Nanostructures; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus	2014
Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units. American journal of infection control, 2014, Volume: 42, Issue:6 Topics: Acinetobacter Infections; Adolescent; Age Factors; Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Immunocompromised Host; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Liver Diseases; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Time Factors	2014
In vivo challenging of polymyxins and levofloxacin eye drop against multidrug-resistant Pseudomonas aeruginosa keratitis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:6 Topics: Animals; Anti-Bacterial Agents; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Keratitis; Levofloxacin; Male; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits	2014
Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:2 Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors	2015
Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. The Journal of infectious diseases, 2015, Apr-15, Volume: 211, Issue:8 Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Meropenem; Mice; Microbial Sensitivity Tests; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins	2015
The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Amikacin; Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; beta-Lactamases; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Thienamycins	2015
In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates. The Journal of international medical research, 2015, Volume: 43, Issue:2 Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Pseudomonas aeruginosa; Pseudomonas Infections	2015
Risk factors for gyrA and parC mutations in Pseudomonas aeruginosa. Infection control and hospital epidemiology, 2015, Volume: 36, Issue:4 Topics: Anti-Bacterial Agents; Case-Control Studies; Cross Infection; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Male; Middle Aged; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Vancomycin	2015
Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 96 Topics: Anti-Bacterial Agents; Chitosan; Cross-Linking Reagents; Cystic Fibrosis; Drug Carriers; Drug Liberation; Humans; Levofloxacin; Microspheres; Particle Size; Powder Diffraction; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Therapy; Spectroscopy, Fourier Transform Infrared; Surface Properties; Technology, Pharmaceutical	2015
Two Different Concentrations of Topical Levofloxacin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Keratitis. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2015, Volume: 31, Issue:10 Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Keratitis; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits	2015
Green foot ulcers. Enfermedades infecciosas y microbiologia clinica, 2017, Volume: 35, Issue:8 Topics: Acetic Acid; Anti-Bacterial Agents; Ciprofloxacin; Combined Modality Therapy; Dermoscopy; Female; Fluorescence; Foot Ulcer; Humans; Immersion; Levofloxacin; Middle Aged; Pigments, Biological; Pseudomonas aeruginosa; Pseudomonas Infections	2017
Does Critical Illness Change Levofloxacin Pharmacokinetics? Antimicrobial agents and chemotherapy, 2015, Dec-14, Volume: 60, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Critical Illness; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Models, Theoretical; Monte Carlo Method; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections	2015
[Palmar ulcer in a splenectomized patient]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2016, Volume: 29, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Diagnosis, Differential; Female; Foot Ulcer; Humans; Levofloxacin; Middle Aged; Postoperative Complications; Pseudomonas Infections; Pyoderma Gangrenosum; Splenectomy	2016
The inhibition of Pseudomonas aeruginosa biofilm formation by micafungin and the enhancement of antimicrobial agent effectiveness in BALB/c mice. Biofouling, 2016, Volume: 32, Issue:7 Topics: Animals; Anti-Bacterial Agents; beta-Glucans; Biofilms; Candida albicans; Drug Therapy, Combination; Echinocandins; Levofloxacin; Lipopeptides; Male; Micafungin; Mice; Mice, Inbred BALB C; Pseudomonas aeruginosa; Pseudomonas Infections; Survival Analysis	2016
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Digestive diseases and sciences, 2010, Volume: 55, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Cefepime; Cefotaxime; Cephalosporins; Drug Resistance, Bacterial; Enterococcus; Escherichia coli Infections; Female; Humans; Infusions, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Liver Cirrhosis; Male; Microbial Sensitivity Tests; Middle Aged; Neutrophils; Ofloxacin; Peritonitis; Pneumococcal Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections	2010
Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis. ORL; journal for oto-rhino-laryngology and its related specialties, 2009, Volume: 71, Issue:5 Topics: Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Comorbidity; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Outpatients; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Rhinitis; Sinusitis; Surgical Wound Infection	2009
Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagnostic microbiology and infectious disease, 2010, Volume: 66, Issue:2 Topics: Aerobiosis; Aerosols; Anaerobiosis; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Ofloxacin; Oxygen; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors	2010
Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. International journal of antimicrobial agents, 2010, Volume: 35, Issue:3 Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan	2010
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Genes, Bacterial; Humans; In Vitro Techniques; Levofloxacin; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins	2010
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. Acta ophthalmologica, 2010, Volume: 88, Issue:4 Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Drug Resistance, Bacterial; Eye Infections, Bacterial; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tobramycin; Vancomycin	2010
Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:5 Topics: Anti-Bacterial Agents; Area Under Curve; Computer Simulation; Databases, Factual; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Urinary Tract Infections	2011
Risk factors for bacteraemia attributable to Pseudomonas aeruginosa resistant to imipenem, levofloxacin, or gentamicin. The Journal of hospital infection, 2011, Volume: 79, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Gentamicins; Humans; Imipenem; Infant; Infant, Newborn; Levofloxacin; Male; Middle Aged; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Young Adult	2011
Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide. International journal of antimicrobial agents, 2012, Volume: 39, Issue:1 Topics: Anti-Bacterial Agents; Ciprofloxacin; Dipeptides; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Membrane Transport Proteins; Microbial Sensitivity Tests; Ofloxacin; Piperazine; Piperazines; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections	2012
Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PloS one, 2011, Volume: 6, Issue:12 Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Phylogeny; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Thienamycins; Time Factors	2011
A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:9 Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Blotting, Western; Colistin; Disease Models, Animal; Drug Therapy, Combination; Electrophoresis, Polyacrylamide Gel; Female; Levofloxacin; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Ofloxacin; Peptides; Pneumonia, Bacterial; Protein Binding; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome	2012
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. International journal of antimicrobial agents, 2012, Volume: 40, Issue:2 Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; Lung Diseases; Male; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections	2012
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. International journal of antimicrobial agents, 2002, Volume: 20, Issue:5 Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins	2002
In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagnostic microbiology and infectious disease, 2003, Volume: 46, Issue:2 Topics: Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Synergism; Evaluation Studies as Topic; Humans; Lactams; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity	2003
Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:11 Topics: Aged; Anti-Infective Agents; Area Under Curve; Blood Proteins; Drug Delivery Systems; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Protein Binding; Pseudomonas Infections; Sepsis; Staphylococcal Infections	2003
[Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002]. Le infezioni in medicina, 2003, Volume: 11, Issue:4 Topics: Body Fluids; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies	2003
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-01, Volume: 38, Issue:7 Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Neutropenia; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Failure	2004
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. Current eye research, 2004, Volume: 28, Issue:5 Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Serratia Infections; Serratia marcescens	2004
E-test method for detecting antibiotic synergy against Pseudomonas aeruginosa from neutropenic patients: a cost-effective approach. The new microbiologica, 2004, Volume: 27, Issue:3 Topics: Anemia; Anti-Bacterial Agents; Cefotaxime; Ceftriaxone; Cost-Benefit Analysis; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Hematologic Neoplasms; Humans; Levofloxacin; Microbial Sensitivity Tests; Neutropenia; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections	2004
Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Feb-15, Volume: 40 Suppl 2 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections	2005
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland. British journal of biomedical science, 2005, Volume: 62, Issue:1 Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia	2005
Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Chemotherapy, 2005, Volume: 51, Issue:2-3 Topics: Anti-Bacterial Agents; Carbapenems; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections	2005
In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa. Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:4 Topics: Amikacin; Animals; Ceftazidime; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity	2005
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. International journal of antimicrobial agents, 2005, Volume: 26, Issue:5 Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones	2005
In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:12 Topics: Aged; Anti-Infective Agents; Area Under Curve; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Levofloxacin; Lung; Middle Aged; Ofloxacin; Pneumonia; Pseudomonas Infections	2005
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Levofloxacin; Male; Middle Aged; Ofloxacin; Pseudomonas Infections; Quinolones; Regression Analysis; Retrospective Studies; Risk Factors	2006
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections. Eye & contact lens, 2006, Volume: 32, Issue:5 Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines	2006
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration]. Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines	2006
An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. International journal of antimicrobial agents, 2007, Volume: 30, Issue:4 Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections	2007
Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis. The British journal of ophthalmology, 2008, Volume: 92, Issue:5 Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Endophthalmitis; Female; Levofloxacin; Male; Microbial Sensitivity Tests; Models, Animal; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus epidermidis; Treatment Outcome; Vancomycin; Vitreous Body	2008
In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:12 Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Female; Levofloxacin; Mice; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections	1996
In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:7 Topics: Alginates; Animals; Anti-Infective Agents; Biofilms; Female; Glucuronic Acid; Guinea Pigs; Hexuronic Acids; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Permeability; Pneumonia, Bacterial; Polytetrafluoroethylene; Pseudomonas aeruginosa; Pseudomonas Infections	1998
Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:1 Topics: Animals; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Intubation; Levofloxacin; Male; Mice; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections	2000
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagnostic microbiology and infectious disease, 2001, Volume: 41, Issue:3 Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Fluoroquinolones; Gatifloxacin; Humans; Lactams; Latin America; Levofloxacin; Microbial Sensitivity Tests; North America; Ofloxacin; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections; Regional Medical Programs; Urinary Tract Infections	2001
Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. International journal of antimicrobial agents, 2002, Volume: 19, Issue:5 Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Selection, Genetic; Time Factors	2002